COSMOS Pharmaceutical Corporation (TYO:3349)
Japan flag Japan · Delayed Price · Currency is JPY
6,302.00
-18.00 (-0.28%)
Apr 17, 2026, 3:30 PM JST

COSMOS Pharmaceutical Cash Flow Statement

Millions JPY. Fiscal year is Jun - May.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '25 May '24 May '23 May '22 May '21
Net Income
42,37233,71932,77333,04838,596
Depreciation & Amortization
22,22919,92417,36815,11013,785
Loss (Gain) From Sale of Assets
508937113-195-4,159
Other Operating Activities
-9,586-8,646-9,034-13,188-9,090
Change in Accounts Receivable
-123-185-254-978
Change in Inventory
-6,182-8,704-11,156-5,853-7,006
Change in Accounts Payable
-2,42317,69722,6276,183-3,491
Change in Other Net Operating Assets
5,6724331,997-2,814-768
Operating Cash Flow
52,46755,17554,43432,19427,875
Operating Cash Flow Growth
-4.91%1.36%69.08%15.49%-57.42%
Capital Expenditures
-53,326-55,810-46,636-43,497-26,064
Sale of Property, Plant & Equipment
-718461,5198,677
Other Investing Activities
-2,122-2,237-2,523-1,739-1,994
Investing Cash Flow
-55,448-57,329-49,113-43,717-19,381
Long-Term Debt Issued
20,00018,40010,000300-
Long-Term Debt Repaid
-5,082-3,193-1,628-1,486-1,486
Net Debt Issued (Repaid)
14,91815,2078,372-1,186-1,486
Repurchase of Common Stock
-2---2-
Common Dividends Paid
-4,959-4,659-3,266-3,266-2,277
Other Financing Activities
-2,240-2,021-1,861-1,768-1,744
Financing Cash Flow
7,7178,5273,245-6,222-5,507
Miscellaneous Cash Flow Adjustments
-----2
Net Cash Flow
4,7366,3738,566-17,7452,985
Free Cash Flow
-859-6357,798-11,3031,811
Free Cash Flow Growth
-----95.42%
Free Cash Flow Margin
-0.08%-0.07%0.94%-1.50%0.25%
Free Cash Flow Per Share
-10.84-8.0198.46-142.7222.87
Cash Interest Paid
258101515260
Cash Income Tax Paid
9,5718,9939,11113,3379,103
Levered Free Cash Flow
-6,530-7,9855,044-15,323-2,005
Unlevered Free Cash Flow
-6,372-7,9235,076-15,291-1,967
Change in Working Capital
-3,0569,24113,214-2,581-11,257
Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.